Table 1.
Baseline patient characteristics.
| N | % | |
|---|---|---|
| Total | 22 | 100 |
| Age at enrollment | ||
| median (range) | 48 (2, 76) | |
| Time from BMT to Study | ||
| median (range) in weeks | 107 (39, 310) | |
| Time from cGVHD onset to Study | ||
| median (range) in months | 41 (10, 241) | |
| No. of cGVHD sites involved | ||
| median (range) | 3 (2, 6) | |
| No. of prior therapies including steroid | ||
| median (range) | 2 (1, 7) | |
| Daily prednisone dose | ||
| median (range), mg | 22.5 (5, 50) | |
| Prior Grade I-IV acute GVHD | 9 | 41 |
| Patient Sex | ||
| Male | 10 | 45 |
| Female | 12 | 55 |
| Diagnosis | ||
| AML | 6 | 27 |
| ALL | 3 | 14 |
| CLL/SLL/PLL | 5 | 23 |
| MDS | 4 | 18 |
| NHL | 2 | 9 |
| CML | 1 | 5 |
| Anemia/Red Cell Disorder | 1 | 5 |
| Conditioning Intensity | ||
| MAC | 12 | 55 |
| RIC | 10 | 45 |
| HLA type (A, B, C, DRB1) | ||
| Matched Unrelated | 11 | 50 |
| Matched Related | 8 | 36 |
| Mismatched Unrelated | 3 | 14 |
| Cell Source | ||
| Bone marrow | 4 | 18 |
| PBSC | 18 | 82 |